Ad is loading...
MENU

CNSP Stock Tickeron detected bullish Stock Pattern: Triangle Symmetrical Top CNSP on October 22, 2024, netting in a 26.37% gain over 1 week

A.I.dvisor
at Tickeron.com
Loading...
+26.37% Gain from a Successful pattern Triangle Symmetrical Top
CNSP - CNS Pharmaceuticals Inc
Tickeron
Ticker: CNSP
Company: CNS Pharmaceuticals
Gain: +26.37%
Confirmed: 10/22/24
Succeeded: 10/22/24
Total length: 8 days
On October 14, 2024, A.I.dvisor detected a Triangle Symmetrical Top Pattern (Bullish) for CNS Pharmaceuticals Inc (CNSP, $0.12). On October 22, 2024, A.I.dvisor confirmed the Bullish pattern, setting a target price of $0.17. On October 22, 2024, CNSP reached the target price resulting in a +2 for traders who took a long position in the stock.

CNSP in +20.65% Uptrend, growing for three consecutive days on November 19, 2024

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CNSP advanced for three days, in of 188 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 60 cases where CNSP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 18, 2024. You may want to consider a long position or call options on CNSP as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

CNSP moved above its 50-day moving average on November 21, 2024 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CNSP broke above its upper Bollinger Band on October 21, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CNSP entered a downward trend on October 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.229) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). CNSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CNSP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CNSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2100 West Loop South
Phone
+1 800 946-9185
Employees
5
Web
https://www.cnspharma.com